Year: 2021
NABH Comments on Surprise Billing
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Letter to CMS on Proposed Measures for IPFQRP
Written by Emily Wilkins (NABH) on . Posted in Letters.
SAMHSA Extends Take-Home Methadone Flexibilities to OTPS for One Year
Written by Emily Wilkins (NABH) on . Posted in Alerts.
Behavioral Health Organizations Release Plan for 988 Crisis Hotline Response
Written by Emily Wilkins (NABH) on . Posted in News Releases.
NABH Letter to Senators Cassidy and Murphy
Written by Administrator on . Posted in Letters.
Joint Letter to OSHA on Workplace Violence
Written by Administrator on . Posted in Letters.
CMS to Require COVID-19 Vaccinations for Medicare and Medicaid Providers
Written by Administrator on . Posted in Resources.
- CMS is requiring that all staff of certain providers and suppliers participating in the Medicare or Medicaid programs receive the COVID-19 vaccine.
- The IFR does not allow for weekly testing in lieu of vaccination.
- The agency expressly preserves an employer’s right to require its employees to be fully vaccinated, regardless of the exemptions provided by the IFC.
- Background: On September 9, 2021 President Biden issued an executive order (EO) entitled “Path out of the Pandemic,” a multifaceted COVID-19 response plan that seeks to boost vaccinations and testing amid the surge in the delta variant. The President’s new plan focuses on six core components, including: (1) “Vaccinating the Unvaccinated;” (2) “Further Protection for the Vaccinated;” (3) “Keeping Schools Safely Open;” (4) “Increased Testing and Requiring Masking;” (5) “Protecting Our Economic Recovery”; and (6) “Improving Care for Those with COVID-19.” To further the mission of this EO, CMS and the Occupational Health Services Administration (OSHA) issued regulations requiring certain individuals in the workforce to be vaccinated against COVID-19. In today’s IFC, CMS indicates that providers and suppliers may be covered by both the OSHA rules and the CMS IFC.
- What’s Next? The final rule is expected to be published in the Federal Register on November 5, 2021, with an expected effective date of January 4, 2022. Comments to the IFC must be received no later than 60 days after the publication of the IFC in the Federal Register. While legal challenges to these guidelines are expected, CMS has already notably indicated in today’s IFC that, to the extent a court may enjoin any part of the rule, it intends that all other provisions or parts of provisions are to remain in effect.
- Applicable Entities — The IFC provides that Medicare- and Medicaid-certified providers and suppliers must require that all applicable staff are fully vaccinated for COVID-19. Specifically, the entities subject to these requirements include:
- ambulatory surgical centers (ASCs);
- hospices;
- psychiatric residential treatment facilities (PRTFs);
- programs of all-inclusive care for the elderly (PACE);
- hospitals, including acute care hospitals, psychiatric hospitals, long term care hospitals, children’s hospitals, hospital swing beds, transplant centers, cancer hospitals, and rehabilitation hospitals;
- long term care (LTC) facilities, including skilled nursing facilities (SNFs) and nursing facilities (NFs);
- intermediate care facilities for individuals with intellectual disabilities (ICFs-IID);
- home health agencies (HHAs);
- comprehensive outpatient rehabilitation facilities (CORFs);
- critical access hospitals (CAHs);
- clinics, rehabilitation agencies, and public health agencies as providers of outpatient physical therapy and speech-language pathology services;
- community mental health centers (CMHCs);
- home infusion therapy (HIT) suppliers;
- rural health clinics (RHCs)/federally qualified health centers (FQHCs); and
- end-stage renal disease (ESRD) facilities.
- In the IFC, CMS refers to the above facilities as residential congregate-care facilities, acute care settings, outpatient clinical care and services, and home-based care, generally. Notably, the requirements outlined in the IFC do not apply to assisted living facilities, group homes, or physician’s offices because they are not regulated by CMS health and safety standards.
- Applicable Staff — CMS is requiring that all staff, regardless of patient contact or clinical responsibility, be fully vaccinated against COVID-19. The IFC stipulates that facility employees; licensed practitioners; students, trainees, and volunteers; and individuals who provide care, treatment, or other services for the facility and/or its patients, under contract or other arrangement, are subject to this requirement. The agency notes that staff who perform their duties outside of a formal clinical setting — such as home health, home infusion therapy, hospice, PACE programs, and therapy staff — are not precluded from the rule. Further, CMS asserts that individuals who provide services 100 percent remotely — including fully remote telehealth or payroll services — are not subject to the vaccination requirements. However, staff that primarily provide services remotely via telework who occasionally encounter fellow staff are still bound by the rulemaking.
- Definition of “Fully Vaccinated” — Under the IFC, an individual is considered to be “fully vaccinated” if it has been two weeks or more since such individual completed a primary vaccination series defined as a single-dose or all doses of a multi-dose vaccine approved by the Food and Drug Administration (FDA). Importantly, individuals who receive vaccines listed by the World Health Organization (WHO) for emergency use but have not been approved or authorized by the FDA will also be counted as fully vaccinated for the purposes of the rulemaking. Additionally, individuals are not required to receive a booster or third dose of a vaccine in order to be considered fully vaccinated. However, providers and suppliers covered by the IFC must have a process for tracking and securely documenting the vaccination status of individuals who have obtained any booster.
- Exceptions — CMS is requiring that applicable providers and suppliers establish and implement a process to allow staff to request an exemption from COVID-19 vaccination requirements based on applicable Federal law. The agency cites certain allergies; recognized medical conditions; or religious beliefs, observances, or practices as possible grounds for exemption. Providers and suppliers covered by the IFC are also required to document exemption requests from the vaccine requirements as well as the outcomes of those requests. Further, the agency is requiring that all applicable providers and suppliers establish a process to ensure the implementation of additional precautions to mitigate the transmission of COVID-19 for all staff who are not fully vaccinated. Notably, CMS expressly preserves an employer’s right to require that employees be fully vaccinated, regardless of the exemptions provided by the IFC.
- Implementation — CMS is providing two implementation phases for the IFC in order to ensure efficiency in carrying out these requirements.
- Phase 1. This phase includes a large majority of provisions in the IFC, including requirements that: (1) all staff have received at least the first dose of the COVID-19 vaccine, or a single dose COVID-19 vaccine, or have requested and/or been granted a lawful exemption to the requirement and (2) facilities have developed and implemented the aforementioned policies and procedures. Phase 1 is effective 30 days after the publication of this IFC in the Federal Register.
- Phase 2. This phase requires that all applicable staff are fully vaccinated for COVID-19, unless granted an exception, which must be fully approved at this phase. Staff who have completed a primary vaccination series by this date are considered to have met these requirements, even if they have yet to complete the 14-day waiting period required for full vaccination. Phase 2 is effective 60 days after the publication of this IFC in the Federal Register.
- Enforcement — CMS plans to issue interpretive guidelines, which include state survey procedures, to aid in assessing compliance with the new requirements among providers and suppliers following the publication of this IFC. The agency provides that non-compliant facilities may be subject to civil money penalties, denial of payment for new admissions, or termination of their Medicare and Medicaid provider agreement.
- Other Provisions — This rule does not provide any prevention and control requirements for PRTFs, RHCs/FQHCs, and HIT suppliers. However, it does require that these entities create procedures in accordance with nationally recognized guidelines to limit the spread of COVID-19. Further, this IFC requires that providers and suppliers retain proper documentation of the vaccination status of each staff member, such as: (1) CDC COVID-19 vaccination card or legible photo of the card; (2) documentation of vaccination from a health care provider or electronic health record; or (3) a state immunization information system record.
NABH Letter to Senate Finance Committee
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH is Proud to Support the Sound the Alarm for Kids! Campaign
Written by Emily Wilkins (NABH) on . Posted in News Releases.
NABH Proposal to Senate Finance Committee on Improving Access to Mental Health and Addiction Treatment Services
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH and Other Organizations Applaud CDC for Adding Mental Illnesses to List of Underlying Conditions Associated with Higher Risk for Severe Covid-19.
Written by Emily Wilkins (NABH) on . Posted in News Releases.
Letter to Chairman Scott on USDOL CMP Parity Authority
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Comments on Hospital Outpatient Prospective Payment System and Price Transparency of Hospital Standard Charges Proposed Rule
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Comments on Physician Pay Schedule
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Comments on Surprise Billing
Written by Jessica on . Posted in Letters.
Multi-District Litigation Settlement
Written by Emily Wilkins (NABH) on . Posted in News Releases.
Advocacy Group Letter on Child Mental Health
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH and a coalition of over 500 national, state, and local organizations urge Congress to protect the federal Medicaid benefits of children in foster care by exempting QRTPs from the IMD exclusion
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Letter to Congress: Education Funding for Youth with Severe Behavioral Health Conditions
Written by Emily Wilkins (NABH) on . Posted in Letters.
CMS Proposes Audio-Only Communication for Telehealth to Treat Mental Health and Substance Use Disorders
Written by Emily Wilkins (NABH) on . Posted in Alerts.
Biden to Nominate Former West Va. Health Official Rahul Gupta as Drug Czar
Written by Emily Wilkins (NABH) on . Posted in Alerts.
NABH Letter to ONDCP: Consultation on National Drug Control Strategy
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Letter to OSHA on Emergency Temporary Standard
Written by Emily Wilkins (NABH) on . Posted in Letters.
The NABH Denial-of-Care Portal is Now Live!
Written by Emily Wilkins (NABH) on . Posted in Alerts.
Letter to United Healthcare on ED Policy
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Comments to CMS on IPPS-IPF 2022
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH and Other Organizations Urge President Biden to Appoint ONDCP Director
Written by Emily Wilkins (NABH) on . Posted in Letters.
988 Crisis Infrastructure Letter to Congressional Leaders
Written by Emily Wilkins (NABH) on . Posted in Letters.
SAMHSA Guide on Suicide for Family and Friends
Written by Emily Wilkins (NABH) on . Posted in Resource.
HALO Letter to HHS about the Provider Relief Fund Deadline
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Comments on Proposed Modifications to HIPAA Privacy Rule
Written by Emily Wilkins (NABH) on . Posted in Letters.
HHS Provides Exemptions for Buprenorphine Prescribers for Fewer Than 30 Patients
Written by Emily Wilkins (NABH) on . Posted in Alerts.
Behavioral Health Slides from MACPAC’s April 2021 Public Meeting
Written by Emily Wilkins (NABH) on . Posted in Resources.
NABH Highlights Residential Treatment as Critical Service for Youth in New White Paper
Written by Emily Wilkins (NABH) on . Posted in Alerts.
NABH Releases Residential Treatment: A Vital Component of the Behavioral Healthcare Continuum
Written by Emily Wilkins (NABH) on . Posted in News Releases.
Joint Letter to OSHA on Inpatient Psych Regulatory Actions
Written by Emily Wilkins (NABH) on . Posted in Letters.
CMS Proposes 2.1% Payment Increase to Per-Diem Base Rate for IPFs in FY 2022
Written by Emily Wilkins (NABH) on . Posted in Alerts.
- Starting in FY 2023, the agency would add a requirement to report Covid-19 Vaccination Coverage Among Healthcare Personnel in the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network web portal;
- For FY 2024, CMS would substitute the Follow-up After Psychiatric Hospitalization (FAPH) measure for the Follow-up After Hospitalization for Mental Illness (FUH) measure. The FAPH includes patients with substance use disorders and also expands the provider types who can provide follow-up care to include primary care providers;
- For FY 2024, the agency would remove the three following measures:
- Alcohol Use Brief Intervention Provided or Offered and Alcohol Use Brief Intervention Provided (SUB-2/2a),
- Tobacco Use Brief Intervention Provided or Offered and Tobacco Use Brief Intervention Provided (TOB-2/2a), and
- Timely Transmission of Transition Record -Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care.
U.S. Labor Department Issues Guidance on Parity Compliance
Written by Emily Wilkins (NABH) on . Posted in Alerts.
- A description of the NQTL, plan terms, and policies at issue;
- Identification of the MH/SUD and medical/surgical benefits to which the NQTL applies;
- The factors used in applying the NQTLs to MH/SUD benefits and medical or surgical benefits;
- The evidentiary standards used for these factors;
- The comparative analyses demonstrating that the processes, strategies, evidentiary standards, and other factors used to apply the NQTLs to MH/SUD benefits, as written and in operation, are comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, and other factors used to apply the NQTLs to medical/surgical benefits in the benefits classification; and
- The specific findings and conclusions reached by the plan or issuer, including any results of the analyses that indicate that the plan or coverage is or is not in compliance with the MHPAEA requirements.
- What information plans and issuers must make available to support their their comparative analyses demonstrating compliance with MHPAEA in their use of NQTLs;
- Examples illustrating when the federal agencies might determine that a comparative analysis of NQTLs is insufficiently specific and detailed;
- The types of documents that plans and issuers should be prepared to make available to the federal agencies to support their analyses and conclusions regarding their NQTL comparative analyses;
- What actions the federal agencies will take if they determine that a plan or issuer has not submitted sufficient information or is not in compliance with MHPAEA;
- Whether state agencies and plan participants and beneficiaries may request to see a plan or issuer’s comparative analysis of its use of NQTLs;
- Which specific NQTLs the federal agencies plan to focus on in the near term when requesting comparative analyses from plans and issuers for review, namely:
- Prior authorization requirements for in-network and out-of-network inpatient services,
- Concurrent review for in-network and out-of-network inpatient and outpatient services,
- Standards for provider admission to participate in a network, including reimbursement rates, and
- Out-of-network reimbursement rates (plan methods for determining usual, customary, and reasonable charges).
Biden Administration Releases Drug-Policy Priorities for Year One
Written by Emily Wilkins (NABH) on . Posted in Alerts.
- Expanding access to evidence-based treatment
- Advancing racial equity in our approach to drug policy
- Enhancing evidence-based harm reduction efforts
- Supporting evidence-based prevention efforts to reduce youth substance use
- Reducing the supply of illicit substances
- Advancing recovery-ready workplaces and expanding the addiction workforce
- Expanding access to recovery support services
Bipartisan Policy Center Report Seeks to Bring Mental Healthcare & Addiction Treatment into the 21st Century
Written by Emily Wilkins (NABH) on . Posted in Resources.
Healthcare Coalition Letter: Medicare Sequester Moratorium
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH, National Council, and NASMHPD Urge CDC to Include Persons with Mental Illness and SUD in First Phase of Covid Vaccinations
Written by Emily Wilkins (NABH) on . Posted in Letters.
NABH Signs MHLG Support Letter for the TREAT Act
Written by Emily Wilkins (NABH) on . Posted in Letters.
Changes to Medicare Coverage for Substance Use Disorder (SUD) Treatment Services
Written by Emily Wilkins (NABH) on . Posted in Issue Brief.
SECTION I: PFS and Other Rules
- CMS adopted the proposal to expand the PFS bundled payments to include all SUDs, not just OUD treatment services.
-
- To avoid duplicate billing for treating individuals who require treatment for more than one substance, HCPCS codes G2086-G2088 should not be billed more than once per month.
-
- HCPCS code G2213: Initiation of medication to treat OUD in the emergency department setting, including assessment, referral to ongoing care, and arranging access to supportive services. (List separately in addition to code for primary procedure).
SECTION II: Coverage for OUD Treatment Services in OTPs
Nasal Naloxone- CMS revised the definition of OUD treatment services to include short-acting opioid antagonist medications, such as naloxone, including nasal and injectable forms.
-
- CMS finalized the proposed drug costs of ASP+0 for nasal naloxone. CMS noted NABH’s concern related to pricing methodology for nasal naloxone and indicated it will monitor utilization of claims data to determine whether payment policies are suppressing naloxone access and need changes in future rulemaking.
- Injectable naloxone is based on contractor pricing. CMS will monitor the data to determine typical dosages and national pricing in future rulemaking.
-
- CMS will consider the need for independent coding for overdose education in future rulemaking.
-
- HCPCS G2215: Take-home supply of nasal naloxone (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure.
Drug Cost | Non-Drug Cost | Total |
89.63 | 2.53 | 92.16 |
-
- HCPCS G2216: Take-home supply of injectable naloxone (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure.
Drug Cost | Non-Drug Cost | Total |
Contracted Price | 2.53 | Contracted Price |
-
- OTPs currently enrolled via CMS-855B may switch to enrollment via CMS-855A without an additional site visit and, if applicable, fingerprinting. This is also true if an OTP is currently enrolled under CMS 855-A and switches to CMS-855B.
- The effective billing date that was established for the OTP under the original enrollment continues to apply.
- Application fees still apply.
-
-
- Therefore, periodic assessments are permitted to continue after the public health emergency ends but are not permitted to be performed via audio-only
- Audio-only is permitted to be included as part of the bundled rate but not as an add-on code.
- Periodic assessments are permitted when medically necessary and documented in the medical record.
-
-
- CMS will consider refinements to account for resource variation for different service intensity, such as induction and maintenance periods.
HHS Announces Delay in Provider Relief Fund Reporting Deadline and Revisions to ‘Lost Revenue’ Definition
Written by Emily Wilkins (NABH) on . Posted in Resources.
NABH Letter to Biden-Harris Transition Team
Written by Emily Wilkins (NABH) on . Posted in Letters.
CMS Expands Medicare Telehealth Coverage for Mental Health and Addiction Treatment Services
Written by Emily Wilkins (NABH) on . Posted in Issue Brief.
- Home Visits, Established Patients (only for treatment of substance use disorders (SUDs) and co-occurring mental health disorder when less complex, lasting typically 25 minutes) (99347 & 99348),
- Group Psychotherapy (other than of a multiple-family group) (90853),
- Psychological and Neuropsychological Testing (96121),
- Care Planning for Patients with Cognitive Impairment (99483),
- Domiciliary, Rest Home, or Custodial Care services (99334),
- Domiciliary, Rest Home, or Custodial Care services (99335),
- Visit Complexity with certain office/outpatient evaluation and management services (G2211),
- Prolonged office or other outpatient evaluation and management service(s) (G2212), and
- New codes for the initial month or subsequent months of psychiatric collaborative care model services (G2214).
- Home Visits, Established Patients (only for the treatment of substance use disorder or co-occurring mental health disorder when moderate to severe, typically lasting 60 minutes) (99349, 99350),
- Psychological and Neuropsychological Testing (96130- 96133, 96136- 96139),
- Therapy Services, Physical, and Occupational Therapy (97161-97168, 97110, 97112, 97116, 97535, 97750, 97755, 97760, 97761, 92521- 92524, 92507),
- Emergency Department Visits (99281-99285),
- Domiciliary, Rest Home, or Custodial Care services, Established patients (99336 & 99337),
- Initial Hospital Care and Hospital Discharge Day Management (99221-99223, 99238, 99239), and
- Subsequent Observation and Observation Discharge Day Management (99217, 99224-99226).
- Brief communication technology-based service, e.g. virtual check-in, by a qualified healthcare professional who cannot report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous seven days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion (G2251); and
- Remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous seven days nor leading to a service or procedure within the next 24 hours or soonest available appointment (G2250).